Business Context and Reporting Period
Calidi Biotherapeutics, Inc. (CLDI), a Delaware corporation and emerging growth company, filed this Form 8-K on May 28, 2026. The report details a material definitive agreement and unregistered sales of equity securities involving an amended and restated warrant issued to an accredited investor.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on the terms of a specific equity transaction.
- Warrant Shares: 17,391,304 unvested shares of common stock.
- Exercise Price: $0.23 per share.
- Minimum Vesting Acquisition Amount: Increased to $1,000,000.
- Vesting Termination Date: Extended to September 30, 2026.
Material Changes
The Company amended and restated a warrant originally issued on May 6, 2026. Key modifications include:
- Stockholder Approval: Exercise of the warrant and issuance of shares are now conditioned upon receipt of stockholder approval.
- Vesting Threshold: The Minimum Vesting Acquisition Amount was doubled from $500,000 to $1,000,000.
- Timeline Extension: The Vesting Termination Date was extended from July 8, 2026, to September 30, 2026.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking guidance or management commentary on operational outlook. Key contingencies and risks identified include:
- Approval Contingency: The warrant cannot be exercised until stockholders approve the issuance.
- Resale Restrictions: Shares issued upon exercise may not be re-offered or sold in the U.S. without an effective registration statement or applicable exemption.
- Regulatory Basis: The issuance relies on Section 4(a)(2) of the Securities Act and Rule 506(b).
Investor Verification Checklist
- Verify the status of the required stockholder approval for warrant exercise.
- Confirm the identity of the accredited investor (Holder) and the nature of the "Minimum Vesting Acquisition Amount" trigger.
- Review the full text of the Amended and Restated Warrant (Exhibit 4.1) for additional covenants not summarized in the filing.
- Monitor future filings for any registration statements required to allow the resale of the 17,391,304 shares.